Back to today’s briefing

Story perspectives

FDA Approves Safer Dosing for Eli Lilly’s Alzheimer’s Drug

7/10/2025

32 6

Summary

Story summary

The US FDA has greenlit a new dosing schedule for Eli Lilly’s Alzheimer’s drug, Kisunla, designed for early-stage patients. This innovative titration method significantly lowers the risk of brain swelling by 40% over six months, ensuring safety without sacrificing the drug's effectiveness against dangerous amyloid plaques. Hope shines brighter for those battling Alzheimer’s.

1 of 1

Story summary

The US FDA has greenlit a new dosing schedule for Eli Lilly’s Alzheimer’s drug, Kisunla, designed for early-stage patients. This innovative titration method significantly lowers the risk of brain swelling by 40% over six months, ensuring safety without sacrificing the drug's effectiveness against dangerous amyloid plaques. Hope shines brighter for those battling Alzheimer’s.